Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, ...
Zacks Investment Research on MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why
In the latest close session, Humacyte, Inc. (HUMA) was down 1.85% at $1.06. The stock trailed the S&P 500, which registered a daily gain of 0.84%. Meanwhile, the Dow experienced a rise of 0.03%, and ...
Zacks Investment Research on MSN
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing
Humacyte, Inc. (HUMA) ended the recent trading session at $0.84, demonstrating a +2.66% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 1.02% ...
Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion –– Seasoned medtech ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host ...
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte (NASDAQ:HUMA) outlined the unmet need in hemodialysis vascular access and highlighted data from its clinical program evaluating the company’s acellular tissue engineered vessel (ATEV) as an ...
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial ...
In the latest trading session, Humacyte, Inc. (HUMA) closed at $5.17, marking a -1.34% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow saw an ...
DURHAM, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial ...
On April 21, 2026, Humacyte entered a third amendment to its distribution agreement with Fresenius Medical Care, regaining sole global rights to develop, commercialize and manage regulatory matters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results